There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Appili Therapeutics Inc Class A (APLIF) and Hologic (HOLX) with bullish sentiments.
Appili Therapeutics Inc Class A (APLIF)
Industrial Alliance Securities analyst Chelsea Stellick maintained a Buy rating on Appili Therapeutics Inc Class A on February 16 and set a price target of C$2.50. The company’s shares closed last Monday at $0.89.
According to TipRanks.com, Stellick is a 4-star analyst with an average return of 46.2% and a 70.6% success rate. Stellick covers the Healthcare sector, focusing on stocks such as ImmunoPrecise Antibodies, Medical Facilities, and Valeo Pharma.
Appili Therapeutics Inc Class A has an analyst consensus of Strong Buy, with a price target consensus of $2.22, which is a 137.8% upside from current levels. In a report issued on February 3, Leede Jones Gable also initiated coverage with a Buy rating on the stock with a C$2.75 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HOLX:
